Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA.
Tran TT, Cabrera NL, Gonzales-Luna AJ, Carlson TJ, Alnezary F, Miller WR, Sakurai A, Dinh AQ, Rydell K, Rios R, Diaz L, Hanson BM, Munita JM, Pedroza C, Shelburne SA, Aitken SL, Garey KW, Dillon R, Puzniak L, Arias CA.
Tran TT, et al. Among authors: puzniak l.
JAC Antimicrob Resist. 2023 Jan 2;5(1):dlac131. doi: 10.1093/jacamr/dlac131. eCollection 2023 Feb.
JAC Antimicrob Resist. 2023.
PMID: 36601551
Free PMC article.